Author:
Herold Ralf,Llinares Jordi
Publisher
Springer Berlin Heidelberg
Reference20 articles.
1. Ad hoc group for the development of implementing guidelines for Directive 2001/20/EC relating to good clinical practice in the conduct of clinical trials on medicinal products for human use (2008) Ethical considerations for clinical trials on medicinal products conducted with the paediatric population.
http://ec.europa.eu/health/files/eudralex/vol-10/ethical_considerations_en.pdf
(accessed 18 September 2011).
2. Eichler HG, Pignatti F, Flamion B, Leufkens H, Breckenridge A (2008) Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov 7(10):818–826. doi:
10.1038/nrd2664
3. Haffner ME, Torrent-Farnell J, Maher PD (2008) Does orphan drug legislation really answer the needs of patients? Lancet 371(9629):2041–2044. doi:
10.1016/S0140-6736(08)60873-9
4. Halpern SD, Karlawish JHT, Berlin JA (2002) The continuing unethical conduct of underpowered clinical trials. JAMA 288(3):358–362
5. Koschmann C, Thomson B, Hawkins DS (2010) No evidence of a trial effect in newly diagnosed pediatric acute lymphoblastic leukemia. Arch Pediatr Adolesc Med 164(3):214–217. doi:
10.1001/archpediatrics.2009.282